Home
Products
COVID-19 POCT
Antigen Rapid Test
VOC-based POCT
Women's Health
Pneumonia
Ainos Pen
AI Nose
Technology
AI Nose
Low-dose interferon
Synthetic RNA
Support
About Us
News
Investors
English
繁體中文
日本語
News Releases
Search by year or by keyword :
Search
Date
Title
2022-06-21
Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan
2021-12-07
Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection
2021-11-03
Ainos SRNA Research Initiative Announces Milestones for mRNA Vaccine Development.
2021-08-16
Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key Executives.
2021-06-14
Ainos Named Exclusive Sales Partner for COVID-19 Antigen Rapid Test Kit in Taiwan.
2021-05-24
Ainos Announces FINRA Approval of Name Change and Ticker Symbol Change to "AIMD", Engages Firm to Explore Listing Requirements of National Securities Exchanges.
2021-04-21
Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."
2020-12-30
Amarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Growth.
2020-09-10
Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board.
2020-08-13
Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics.
«
1
2
3
4
5
»
CONTACT US
United States:
8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108
+1 (858) 869-2986
Taiwan:
10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302 , Taiwan (R.O.C.)
+886 (0)3-550-5199
COMPANY
Products
AI Nose
Low-Dose Oral Interferon
Synthetic RNA
News
Privacy policy
INVESTORS
Overview
Stock Info
IR News
Governance
Financials
Alerts
OUR AGENTS
INABATA & CO., LTD.
TAIWAN ORIACT CO., LTD.
Copyright © 2023 Ainos Inc. All rights reserved.